Asmacure has commenced phase 1/2 trial of ASM-024 dry powder for inhalation (DPI) formulation with multi-functional mechanism of action with nicotinic and muscarinic effects.
In pre-clinical asthma models ASM-024 exhibited the capabilities of inhibitory effects on inflammation, bronchoprotection and smooth muscle relaxation.
Asmacure founder and chief medical officer Yvon Cormier said the anti-inflammatory, bronchoprotection and smooth muscle relaxation effects shown in pre-clinical asthma models and the results from phase 2 programme indicate that ASM-024 is a potent new treatment option for individuals with asthma.
"The novel mechanism of action could prove beneficial for patients with moderate to severe asthma and COPD where the dual nicotinic and muscarinic effects could provide added benefit," Cormier added.
The trial is desined to have single-ascending dose and repeat administration phases.
The study bridges into a phase 2 study in moderate asthmatics, which is expected to commence in the third quarter of 2013.
